Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Huh-7 cells were transplanted into nude mice and co-cultured with PLK1 siRNA or control siRNA, and tumor progression was compared with controls.
|
22826617 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Also, FBXW7, MCL1 and PLK1 may be relevant predictive markers of tumor progression and response to paclitaxel treatment.
|
27409838 |
2016 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our results show that the Plk1 phosphorylation sites in FoxM1b serve as a regulator for its repressor function, and they provide insights into how FoxM1b inhibits differentiation genes and activates proliferation genes during cancer progression.
|
28387346 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In vivo, Plk1 inhibitors killed CD133(+) colon cancer cells leading to complete growth arrest of colon cancer stem cell-derived xenografts, whereas chemotherapeutic agents only slowed tumor progression.
|
22753241 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PLK1 expression was determined in 160 gastric carcinoma patients by immunohistochemistry and compared with p53 expression and the proliferating cell nuclear antigen-labeling index (PCNA-LI) to evaluate the effect of PLK1 on tumor progression.
|
16645325 |
2006 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of PLK1 by shRNA or BI 2536 in Pim1-overexpressing prostate cancer xenograft models resulted in a dramatic inhibition of tumor progression.
|
24771642 |
2014 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These data suggest that a high level expression of PLK1 confers tumor progression advantages to urothelial cancer cells, although other factors are also involved.
|
16837776 |
2006 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Indeed, allosteric or genetic inhibition of phospho-Ser338 CRAF impairs Plk1 activation and accumulation at the kinetochores, causing prometaphase arrest, whereas a phospho-mimetic Ser338D CRAF mutant potentiates Plk1 activation, mitosis and tumor progression in mice.
|
22081024 |
2011 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The mechanisms and significance of dysregulation of Stat3 and PLK1 in carcinogenesis and cancer progression are unclear.
|
22108192 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these findings establish a critical role for Plk1 in regulating biosynthesis in cancer cells, exemplifying how cell cycle progression and metabolic reprogramming are coordinated for cancer progression.
|
29138396 |
2017 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Up-regulation of PLK1 was found in tumorigenesis and tumor progression of diverse cancers.
|
28915707 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although there is a collection of scientific reports showing how Plk1 can contribute to tumor progression, recent data from different laboratories using mouse models, show that Plk1 can surprisingly play as a tumor suppressor.
|
30862113 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
As hyper-activation of PLK-1 is broadly associated with poor prognosis and cancer progression, it is one of the most extensively studied mitotic kinases.
|
28415805 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
|
22249248 |
2012 |